IR Pharma company logo
  • Company overview
  • Meet the team
  • Why we're different;
  • Technology - The drug development process at IRP; The Drug Evaluation Process; Model systems
  • Portfolio
  • Contact us

  • Publication strategy planning
    is offered as part of IR Pharma's
    comprehensive package


    IR Pharma will have a presence
    at the following conferences.
    Contact us to arrange
    a meeting with one of the team.

    May 19-24, 2017
    American Thoracic Society
    Annual Conference.
    Washington DC, USA.

    September 9-13, 2017
    European Respiratory Society
    Milan, Italy.

    Mechanism assays,
    modelling paradigms . . .

    IR Pharma offers a wide range of services that may not be available through other Contract Research Organisations thanks to the company's clinical and academic links:

    Human tissue assays

    • Human tissue assays (phenotyped patients, donor tissue from transplantation programmes);
    • Organ bath and precision lung cut slices (PCLS) for airway and vessel in vitro functional expts. Other tissues can be studied outside the lung if project requires it;
    • Human ex vivo whole lung assay (LPS inhalation & assessment of neutrophilia and biomarkers).

    Additional in vivo capabilities

    • Pharmacokinetic support;
    • In vivo proof of mechanism assays (eg. p65 NK-KB DNA binding for IKK-2 programmes in cell based assays, human tissue and in vivo models);
    • Modelling paradigms to assess if systemic exposure necessary for lung efficacy;
    • In vivo sensory nerve irritancy assays to evaluate whether inhaled compounds cause cough;
    • Assessment of therapeutic ratio (eg. for glucocorticoid programmes - femur growth plate and serum biochemistry);
    • Access to colonies of KO mice for target validation purposes.

    Project management capabilities

  • Extensive project management experience gained by working for and collaborating with Pharma;
  • Access to clinical collaborators/models;
  • publication strategy if required.